Dexmedetomidine attenuates LPS-induced acute lung injury via activation of mitochondrial autophagy

Acute lung injury (ALI) is a life-threatening condition characterized by severe inflammation and oxidative damage in the lungs, and it currently lacks targeted drug therapies. Dexmedetomidine (Dex) is a sedative drug already used in intensive care units, but this study asks whether it can also protect the lungs by activating a cellular 'self-cleaning' process called mitophagy — the selective removal of damaged mitochondria. Researchers exposed rats to lipopolysaccharide (LPS, a bacterial toxin) to mimic ALI, and also treated rat lung immune cells (alveolar macrophages) with LPS in a dish, then gave Dex in both settings. Dex markedly reduced lung swelling, tissue damage, and levels of inflammatory proteins (IL-6 and TNF-α), while also cutting down harmful reactive oxygen species (ROS). The protective effect worked through a specific mitochondrial quality-control pathway called PINK1/Parkin, which tags and clears damaged mitochondria. Crucially, when the researchers chemically blocked this mitophagy pathway, Dex lost most of its protective benefit — confirming the mechanism rather than just showing an association. The findings suggest that drugs which activate mitophagy in lung immune cells could be a viable strategy for treating ALI, and they provide a mechanistic rationale for the protective effects of Dex already observed clinically.

• Dex treatment significantly reduced the lung wet-to-dry ratio and improved histopathological damage scores in LPS-exposed rats, indicating reduced pulmonary edema and tissue injury.
• Dex decreased serum and cell-culture supernatant levels of IL-6 and TNF-α, and lowered intracellular ROS in both lung tissue and NR8383 alveolar macrophages, demonstrating dual anti-inflammatory and antioxidant effects.
• Dex significantly upregulated PINK1, Parkin, and LC3B expression at both protein and mRNA levels and restored mitochondrial membrane potential (MMP) in LPS-injured cells; pharmacological mitophagy inhibition with 3-MA reversed these protective effects, while the autophagy agonist Hexadecadrol further enhanced them, causally linking PINK1/Parkin-mediated mitophagy to the drug's mechanism of action.

Male Sprague–Dawley rats were randomly assigned to control, LPS, and LPS + Dex groups to establish an in vivo ALI model. In parallel, NR8383 rat alveolar macrophages were treated with LPS and Dex in vitro. Outcomes were assessed using ELISA (IL-6, TNF-α), lung wet-to-dry ratio, histological examination, TUNEL assay (cell death), Western blot and RT-qPCR (PINK1, Parkin, LC3B), CCK-8 cell viability assay, and mitochondrial membrane potential measurement. Mechanistic causality was tested by pharmacological inhibition of mitophagy (3-methyladenine, 3-MA) and activation (Hexadecadrol).

As an animal and cell-line study, findings cannot be directly extrapolated to human ALI patients; the clinical Dex doses and timing used in ICU settings may differ substantially from the experimental protocol. The study does not establish whether the PINK1/Parkin pathway is the sole or dominant mechanism, nor does it rule out parallel contributions from other autophagy receptors (e.g., FUNDC1 or BNIP3). Rat alveolar macrophages (NR8383 cell line) may not fully recapitulate the heterogeneous immune-cell landscape of human lungs. The next critical experiments would be genetic knockout or knockin of PINK1/Parkin in a rodent ALI model and, ultimately, ex vivo human lung tissue validation.

This study extends [§136], which showed that enhancing mitophagy via PINK1/Parkin suppresses NLRP3 inflammasome-driven inflammatory injury in peripheral nerve repair, by demonstrating the same pathway is therapeutically actionable with a clinically available drug (Dex) in pulmonary macrophages. It parallels [§134], which examines PINK1/Parkin-linked mitophagy dysregulation in obesity-related cardiomyopathy, reinforcing that this pathway is a cross-organ regulator of mitochondrial homeostasis under inflammatory or metabolic stress, though the directional role of mitophagy (protective here, potentially maladaptive there) differs by context and warrants direct comparison. The work also parallels [§124], where removing dysfunctional mitochondria alleviates inflammatory tissue damage in rheumatoid arthritis through mitophagy, supporting a generalizable principle that mitochondrial quality control is a druggable node in immune-mediated injury. Together, these studies suggest the corpus is converging on PINK1/Parkin mitophagy as a conserved protective mechanism across multiple inflammatory disease models, with the current article contributing a pharmacological proof-of-concept angle that complements more mechanistic genetic studies in the same topic.

• Hirudin Promotes Peripheral Nerve Repair by Enhancing Mitophagy to Suppress NLRP3 Inflammasome Activation
  Directly parallel mechanism: hirudin activates PINK1/Parkin mitophagy to suppress NLRP3-driven inflammation in peripheral nerve injury, making it the closest mechanistic comparator to Dex in lung macrophages.
• Cardiomyocyte BMAL1 deficiency worsens obesity-related cardiomyopathy with heightened PINK1/Parkin-linked mitophagy and mitochondrial dysfunction
  Both studies interrogate PINK1/Parkin mitophagy under pathological stress, but cardiomyocyte BMAL1 deficiency appears to heighten rather than beneficially engage this pathway, offering a contrasting context that illuminates when mitophagy is protective versus insufficient.
• Exercise hormone irisin alleviates rheumatoid arthritis by removing dysfunctional mitochondria
  Irisin alleviates rheumatoid arthritis by clearing dysfunctional mitochondria via mitophagy, providing a cross-disease parallel that reinforces the therapeutic logic of mitophagy activation with a different pharmacological agent and tissue type.
• Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
  Examines how mitochondrial RNA release during aging drives inflammation and senescence — a complementary upstream mechanism to mitophagy failure that contextualizes why maintaining mitochondrial clearance (as Dex does here) is anti-inflammatory.